Biotech investor’s focus on small caps, but Gilead Sciences, valued at $147 billion, is quietly strengthening its pipeline in oncology and next-gen cell therapy. Stock surged 26.9% YTD, showing strength in core business, particularly in HIV franchise. Approval of YES2GO injectable for HIV prevention marks significant milestone, with promising growth in oncology with Trodelvy. Gilead’s financial discipline supports increased revenue and EPS guidance for 2025, despite trading at a discount. Wall Street rates stock a “Moderate Buy” with upside potential. Gilead presents growth opportunities in HIV prevention, oncology, and liver disease, with 52 clinical programs in its pipeline. Strong balance sheet and reinvestment in innovation make Gilead an attractive option for patient investors seeking stability and upside potential in biotech.

Read more at Yahoo Finance: This Overlooked Biotech Stock Is a Buy for Its Hidden Strengths